Threotech to present latest clinical data on Magtein® at Vitafoods Europe

ThreoTech, LLC, exclusive global distributor of Magtein^®, will discuss the science and market potential of the unique magnesium form in a comprehensive speaking program at Vitafoods Europe.

Magtein is the patented proprietary form of magnesium L-threonate, a scientifically advanced magnesium compound developed through pioneering neuroscience research to support magnesium levels in the brain. Extensively studied in multiple peer-reviewed human clinical trials, Magtein is the most researched branded magnesium L-threonate available and features in over 400 products worldwide.

Most recently, a new clinical trial has further strengthened the science behind Magtein, examining its effects across multiple markers of psychological function, nervous system performance, and the body’s response to mental and physical demands.[1]

At Vitafoods Europe (Stand 3J6, Fira Barcelona, May 5–7, 2026), Magtein’s CEO Jennifer Gu, PhD, and Adrian Lopresti, PhD, will present the findings in an exclusive joint session.

The presentation will be the flagship session of a comprehensive speaking program which will also include:

A session on the new research including live, interactive cognitive assessments, giving attendees a firsthand experience of how brain function is measured and improved
An overview of the global magnesium category, drawing on the latest consumer trends, the channels driving growth, and the countries representing the greatest commercial opportunities for Magtein
An exploration of how an integrated approach to social media, PR and high-profile partnerships is building deep, lasting consumer trust around Magtein
A practical guide to the product development science behind Magtein, covering next-generation delivery formats and the formulation strategies that have successfully brought Magtein-powered products to market worldwide.

Rory Lipsky, EVP, Magtein (ThreoTech, LLC), said: “The science behind Magtein has never been stronger. The findings of the most recent clinical study, for example, are compelling, and we’re looking forward to sharing them at Vitafoods Europe, which is the most important event for our European and global partners. Our 2026 program is our most comprehensive to date: if you want to understand why Magtein is the most clinically studied magnesium L-threonate on the market, we’d definitely encourage you to attend.”

Meanwhile, Magtein has been named a finalist in three categories at the 2026 NutraIngredients Europe Awards. It has been shortlisted for Ingredient of the Year: Healthspan, Ingredient of the Year: Mind and Mood, and Nutrition Research Project for the Magtein Brain Magnesium Research Program.

Magtein was authorized as a novel food in the UK this year, having been granted Novel Food status in the EU in 2024. In the US, it has had FDA GRAS approval since 2012, and it is also approved as safe for use in consumer products in Canada, Japan, Turkey, India and Thailand.

All speaking sessions will be held at Stand 3J6 and are open to all registered Vitafoods attendees.

^[1] Lopresti AL, Smith SJ. The effects of magnesium L‑threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double‑blind, placebo‑controlled trial. Front Nutr. 2025;12:1729164. doi:10.3389/fnut.2025.1729164

Innovations in Food (& Beverage) Technology is a quarterly magazine distributed globally both in Print and Digital formats. www.innovationsfood.com. Twitter: @Innovfoodtech. Instagram: @innovationsinfoodtechnology. Linkedin: www.linkedin.com/in/terry-prior52